{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"23.2","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Confirmed response rate will be reported as the number of participants achieving either a complete response or partial response (using RECIST v1.1) divided by the number of evaluable participants. In order for a participant to be a confirmed objective responder, they must achieve a PR or CR on consecutive evaluations, at least 4 weeks apart.\n\nComplete Response (CR): Disappearance of all target lesions and normalization of tumor biomarkers.\n\nPartial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"Treatment (Akt Inhibitor MK2206)"}],"paramType":"NUMBER","populationDescription":"Two patients were deemed ineligible for this endpoint due to eligibility criteria not being met. Therefore, this endpoint is reported using 14 eligible patients.","reportingStatus":"POSTED","timeFrame":"Up to 32 weeks","title":"Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1","type":"PRIMARY","unitOfMeasure":"percentage of patients"}